Corporate Snapshot
The Medical House PLC ("TMH" or "the Company") designs drug delivery device platforms for the pharmaceutical and biotechnology industries. Employing the right delivery device can be critical for determining treatment adherence and efficacy. TMH's primary product line is a family of devices known as the ASI disposable autoinjector platform, which is intended to offer patients an easy, safe, and convenient means of self-injection. The ASI autoinjector is entirely automated—from needle insertion and medication injection to needle withdrawal and full retraction back into the device. When the shot is completed, the entire device unit is disposed. With an ASI autoinjector device, patients never see nor handle a syringe or needle, thereby reducing the anxiety that many people have about self-injections and eliminating the risk of accidental needlestick injuries. The ASI autoinjector also removes guesswork about dosing. Its prefilled syringes and automated delivery process ensure that patients receive accurate and consistent doses—a feature designed to improve treatment compliance and efficacy as well as reduce users' dependence on clinicians. The Company has also developed a second delivery device platform—reusable needle-free jet injectors. TMH has received Europe's CE Mark and the U.S. FDA's 510(k) clearance for versions of the ASI autoinjector and the reusable needle-free jet injectors. Several entities have licensed TMH's platforms as a means to deliver proprietary medications. TMH has partnerships for its ASI autoinjector platform with Dr. Reddy's Laboratories Ltd. (RDY-NYSE), Catalent Pharma Solutions, Inc. and Stallergenes SA (GENP-EPA), and a European government agency, as well as with an undisclosed global pharmaceutical partner that licensed an ASI autoinjector system in an agreement with a minimum of £15 million in technology access fees projected over its first six years. Further, TMH has an agreement to launch its needle-free jet injector technology for injection of human Growth Hormone (hGH) in collaboration with Merck Serono International S.A.
* The Corporate Snapshot was last updated on March 31, 2009.
Latest Research
Quarterly
Update
2009-03-31
Click to View
Executive
Informational
Overview
2008-11-10
Click to View